ANTEPSIN

SUCRALFATE

Sucralfate tablet is indicated in the treatment of acute, nonmalignant gastric and duodenal ulcers. Maintenance therapy to prevent the recurrence of duodenal ulcers. Sucralfate suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Chelating complex

Aminoglycosides like Streptomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Streptomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

Adult: Usual dose 1 gm 4 times daily to be taken 1 hour before meals and at bed time. Maximum daily dose is 8 gm. Four to six weeks treatment is usually needed for ulcer healing but upto twelve weeks may be necessary in resistant cases. Antacids may be used as required for relief of pain, but should not be taken half an hour before or after Gastalfet. Elderly: There are no special dosage requirements for elderly patients but as with all medicines the lowest effective dose should be used. children: Safety and efficacy in children have not been established

Concomitant use of sucralfate may reduce the bioavailability of certain drugs as has been observed in animal studies with tetracycline, phenytoin and cimetidine and in human studies with digoxin. Administration of sucralfate with any of these drugs should be separated by two hours. Since sucralfate may hinder warfarin absorption, caution should be exercised when these two drugs are used together.

There are no known contraindications

The incidence and severity of side effects from sucralfate are very low. Mild side effect like constipation has been reported in some patients.

Although animal studies show no evidence of foetal malformation, safety in pregnant women has not been established and Sucralfate should be used in pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised when sucralfate is administered to nursing mothers.

There is no experience in human with overdosage

The product should only be used with caution in patients with renal dysfunction

Store at 20-258 C.